Panitumumab (anti-EGFR)
Based on 1 Customer Validation
Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer.
For research use only. We do not sell to patients.
- Purity: 99.02%
- Molecular Weight:144.32 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All EGFR Isoforms
More
Biological Activity
Human IgG2 kappa
Human
EGFR
Panitumumab (2 nM-2 μM, 3 h) (anti-EGFR) inhibits ligand-dependent autophosphorylation in EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells[3].
Panitumumab (0-200 μg/mL, 48 h) (anti-EGFR) inhibits the proliferation of DLD-1 cells[4].
Panitumumab (80 μg/mL, 24 h) (anti-EGFR) increase beclin-1 (a marker of autophagy) levels in Caco-2 cells and DLD-1 cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells
-
Concentration:2, 20, 200, 2000 nM
-
Incubation Time:3 h
-
Result:Inhibited ligand-induced autophosphorylation of EGFR.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NCI-H1975 and NCI-H1650 xenografts[3]
-
Dosage:25, 100, or 500 μg/mouse
-
Administration:Intraperitoneal injection (i.p.), twice a week
-
Result:Inhibited ligand-induced EGFR phosphorylation, tumor growth, and markers of proliferation.
Decreased Ki-67 and phospho- mitogen-activated protein kinase (pMAPK) staining in both xenografts.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
P00533-1
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG2-kappa
ELISA, FACS, Functional assay
-
Flow Cytometry analysis of A431 cells labelling EGFR (red) with Panitumumab (anti-EGFR) (HY-P99041A). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG2 kappa (HY-P99002). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 144.32 kDa
-
Color Colorless to light yellow
-
SMILES
[Panitumumab (anti-EGFR)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Giannopoulou E, et al. Autophagy: novel action of panitumumab in colon cancer. Anticancer Res. 2009 Dec;29(12):5077-82. PMID: 20044619.. . . [Content Brief]
[2]. Yu Jo Chua, et al. Panitumumab. Drugs Today (Barc). 2006 Nov;42(11):711-9. [Content Brief]
[3]. Stefan Stremitzer, et al. Panitumumab safety for treating colorectal cancer. Expert Opin Drug Saf. 2014 Jun;13(6):843-51. [Content Brief]
[4]. Daniel J. Freeman, et al. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol Cancer Ther (2009) 8 (6): 1536–1546. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Panitumumab (anti-EGFR) Related Classifications
HY-P99041A Related Classifications
Powered by Bioz